Kymera Therapeutics, Inc 8-K, filed Jun 27, 2025
Kymera Therapeutics, Inc. (KYMR)
About this 8-K
Kymera Therapeutics, Inc filed this 8-K on June 27, 2025, reporting on events of June 25, 2025.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 27, 2025 (
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
Kymera Therapeutics, Inc.
| (Address of principal executive offices, including zip code) |
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trade Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2025. The final voting results are set forth below.
Proposal 1 – Election of Class II Director Nominees
The shareholders of the Company elected Jeffrey Albers, J.D., MBA and Felix J. Baker, Ph.D. as Class II directors of the Company, each to hold office for a three-year term ending at the annual meeting of shareholders to be held in 2028 and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. The results of the shareholders’ vote with respect to the election of the Class II directors were as follows:
| Votes For |
Votes Withheld |
Broker Non-Votes |
||||||||||
| Jeffrey Albers, J.D., MBA |
55,765,189 | 3,142,251 | 2,748,381 | |||||||||
| Felix J. Baker, Ph.D. |
51,745,887 | 7,161,553 | 2,748,381 | |||||||||
Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company’s Named Executive Officers
The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The results of the shareholders’ non-binding, advisory vote with respect to such approval were as follows:
| Votes For |
Votes Against |
Abstain |
Broker | |||
| 54,364,880 | 4,531,413 | 11,147 | 2,748,381 |
Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm
The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the shareholders’ vote with respect to such ratification were as follows:
| Votes For |
Votes Against |
Abstain |
Broker | |||
| 61,644,725 | 4,768 | 6,328 | 0 |
No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Kymera Therapeutics, Inc. | ||||||
| Date: June 27, 2025 | By: | /s/ Nello Mainolfi | ||||
| Nello Mainolfi, Ph.D. | ||||||
| President and Chief Executive Officer | ||||||